Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19-chimeric Antigen Receptor T Cells”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)UnknownNCT03110640
What this trial is testing

Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma

Who this might be right for
B-cell Adult Acute Lymphoblastic LeukemiaB-cell Chronic Lymphocytic LeukemiaAdult Acute Lymphoblastic Leukemia in Remission+2 more
First Affiliated Hospital of Wenzhou Medical University 20
Very early researchLooking for participantsNCT07241468
What this trial is testing

An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease

Who this might be right for
Relapsed/Refractory Immune NephropathyRelapsed/Refractory Immune-mediated Kidney Disease
Changhai Hospital 36
Testing effectiveness (Phase 2)Looking for participantsNCT05952804
What this trial is testing

IVIG for Infection Prevention After CAR-T-Cell Therapy

Who this might be right for
Hematologic Malignancies
Fred Hutchinson Cancer Center 150
Early research (Phase 1)Study completedNCT04231747
What this trial is testing

CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma Non-HodgkinAgressive LymphomaDiffuse-large B-cell Lymphoma (DLBCL)
Juno Therapeutics, a Subsidiary of Celgene 24
Early research (Phase 1)Not Yet RecruitingNCT07166549
What this trial is testing

Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)

Who this might be right for
B Cell MalignanciesB-cell LeukemiaB Cell Lymphoma+2 more
University Hospital, Basel, Switzerland 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT03155191
What this trial is testing

Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia

Who this might be right for
Lymphoblastic Leukemia, Acute Adult
Takara Bio Inc. 21
Early research (Phase 1)UnknownNCT04204161
What this trial is testing

A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma

Who this might be right for
Relapsed B-cell Acute Lymphoblastic Leukemia, ChildhoodRefractory B-cell Acute Lymphoblastic Leukemia, ChildhoodRelapsed/Refractory B-cell Lymphoma, Childhood
Shenzhen BinDeBio Ltd. 30
Testing effectiveness (Phase 2)Looking for participantsNCT04276870
What this trial is testing

Orphan Indications for CD19 Redirected Autologous T Cells

Who this might be right for
Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALLInfants With Very High Risk KMT2A B-ALLPatients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation
Stephan Grupp MD PhD 133
Testing effectiveness (Phase 2)Study completedNCT04690192
What this trial is testing

CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

Who this might be right for
Large B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China 30
Early research (Phase 1)UnknownNCT05381181
What this trial is testing

Safety and Efficacy Evaluation of Next-generation CD19-UCART

Who this might be right for
Acute Lymphoblastic LeukemiaNon Hodgkin Lymphoma
Bioray Laboratories 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT03573700
What this trial is testing

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia, Refractory
St. Jude Children's Research Hospital 24
Early research (Phase 1)Looking for participantsNCT06892145
What this trial is testing

Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE

Who this might be right for
Systemic Lupus Erythematosus (SLE)Refractory
Chongqing Precision Biotech Co., Ltd 12
Very early researchNot Yet RecruitingNCT07077330
What this trial is testing

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms

Who this might be right for
Relapsed or Refractory Plasma Cell Neoplasms
Chinese PLA General Hospital 20
Early research (Phase 1)UnknownNCT04100187
What this trial is testing

Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia

Who this might be right for
Leukemia
Kecellitics Biotech Company Ltd 100
Early research (Phase 1)UnknownNCT03018093
What this trial is testing

A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL

Who this might be right for
Relapsed or Refractory Acute Lymphoblastic Leukemia
Shanghai AbelZeta Ltd. 20
Early research (Phase 1)UnknownNCT03298828
What this trial is testing

CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Who this might be right for
Acute Lymphoblastic LeukemiaBurkitt Lymphoma
Third Military Medical University 30
Testing effectiveness (Phase 2)Looking for participantsNCT07252336
What this trial is testing

Study of CAR-T Cells in Primary Ph+All

Who this might be right for
ALL
Zhejiang University 50
Testing effectiveness (Phase 2)Looking for participantsNCT06788964
What this trial is testing

Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)

Who this might be right for
Relapsed or Refractory Large B-cell Lymphoma
University of Utah 29
Testing effectiveness (Phase 2)Looking for participantsNCT06585514
What this trial is testing

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus

Who this might be right for
Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)
Beijing GoBroad Hospital 18
Not applicableLooking for participantsNCT05988216
What this trial is testing

Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus

Who this might be right for
Systemic Lupus Erythematosus (SLE)
Bioray Laboratories 12
Next Page